@courtney.hollidayy's tirzepatide injection video, fact-checked

What did @courtney.hollidayy actually say?

Courtney is injecting compounded tirzepatide at what she calls a "micro dose" of 0.15 mg (she says "15 units," which suggests she's drawing from a vial using an insulin syringe). She gets it from a compounding pharmacy called Frame Meds, pays out of pocket, and drives from Virginia to North Carolina to receive shipments because Frame Meds doesn't ship to her home state. She says she switched from semaglutide because of bad side effects, and now reports virtually none on tirzepatide.

Her core claims: microdosing helps with acne, bloating, PCOS symptoms, and rheumatoid inflammation. She's no longer taking it for weight loss but to maintain a 95-pound loss. She recommends eating high protein on injection day to reduce nausea. She promotes Frame Meds by name and says she has them linked in her bio.

Does the science back this up?

The weight maintenance claim has the most legitimate scientific grounding. The rest gets shaky fast.

Tirzepatide's mechanism, acting as a dual GIP and GLP-1 receptor agonist, does produce real metabolic effects beyond weight loss. The SURMOUNT-3 trial (Wadden et al., 2023, NEJM) showed significant weight maintenance when patients continued tirzepatide after an intensive lifestyle intervention. So using a low dose to hold a loss is not medically absurd.

For PCOS, there is emerging evidence that GLP-1 receptor agonists improve insulin sensitivity and androgen levels, which can indirectly reduce symptoms like acne (Jensterle et al., 2019, Frontiers in Endocrinology). But this research is mostly on semaglutide, not tirzepatide specifically, and it's far from settled science. Calling it a fix for PCOS overstates what we actually know.

The rheumatoid arthritis inflammation claim is the weakest. Some preclinical and observational data suggest GLP-1 agonists may have anti-inflammatory properties (Drucker, 2016, Cell Metabolism), but no clinical trial has established tirzepatide as a treatment for RA. That's a big leap she's making without much to stand on.

What did they get wrong (or right)?

She got some things right. High-protein eating on injection day is a reasonable practical tip, not a medical myth. The general side effect profile difference between semaglutide and tirzepatide is real: SURPASS-CVOT and direct comparison data suggest tirzepatide can be better tolerated in some patients.

But here's what she got wrong, and it matters. She's driving across state lines to receive a controlled-access compounded drug because her state restricts it. That's not a life hack. That's a regulatory red flag she's presenting as a convenience tip. Virginia's restrictions on compounded tirzepatide exist for patient protection reasons.

She also says Frame Meds compounded tirzepatide includes B12, presenting that as a positive feature. Compounded drugs are not FDA-approved and are not equivalent to brand-name Zepbound or Mounjaro. B12 additions are not clinically standardized. The FDA has raised concerns about the quality and dosing consistency of compounded GLP-1 drugs (FDA Drug Shortages, 2024).

Her claim that microdosing helps with "rheumatoid inflammation" specifically is unsubstantiated. She should not be saying that, and her audience probably shouldn't be acting on it.

What should you actually know?

Compounded tirzepatide is legal in some states under FDA shortage provisions, but the shortage designation for tirzepatide was updated in 2024, which changes what compounders can legally do. If you're sourcing it from a pharmacy that ships around state restrictions, that's worth understanding before you order.

Microdosing GLP-1 drugs is genuinely being explored, but there's no standardized clinical definition of what a "micro dose" means, no dose-response data for off-label uses like acne or inflammation, and no guidance from any prescribing body on how to titrate this way safely. A 0.15 mg dose of tirzepatide is below the lowest approved starting dose (2.5 mg), so the pharmacological effect at that level is not well characterized.

If you have PCOS or RA and you're interested in whether a GLP-1 drug might help you, that's a legitimate conversation to have with an actual prescriber who knows your full medical history, not a TikTok video with a bio link.

The bottom line on Frame Meds and bio links

Courtney says she has Frame Meds "linked to my bio" twice. That makes this at least partly a promotional post, whether or not it's disclosed as paid. Compounding pharmacies vary widely in quality, testing standards, and regulatory compliance. No single pharmacy endorsement from a social media creator should be taken as a clinical recommendation. The FDA's 2024 guidance on compounded semaglutide and tirzepatide quality concerns applies broadly to this category of product.